MARKET COMPOSITE
Market TodayThemes and Stocks SummaryThematic Stock SearchDaily Refresh Schedule
ETON - Eton Pharmaceuticals Inc
$8.15
0.24(3.03%)9:00:00 PM 3/1/2021
Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing pharmaceutical products. The company offers Biorphen, a phenylephrine hydrochloride injection for the treatment of clinically important hypotension resulting primarily from vasodilation in the setting of anesthesia. It also develops EM-100, an ophthalmic product for the treatment of allergic conjunctivitis; ET-203, which is injectable product candidates for use in the hospital setting; ET-103, an oral liquid product candidate for hypothyroidism; ET-101 and ET-104, which are oral liquid product candidates for neurological indications; DS-300 and DS-100, which are injectable product candidates; and ET-105, a lamotrigine for oral suspension. Eton Pharmaceuticals, Inc. was founded in 2017 and is based in Deer Park, Illinois.
Stock Chart

Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from 

Finra

Moving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.

Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.

No summary
Related Topics
leak data

Related Topics

Peers

Related Peers

Stock news

    02/16/2021ETON
    Eton Pharmaceuticals to Participate in 10th Annual SVB Leerink Global Healthcare Conference

    DEER PARK, Ill., Feb. 16, 2021 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative treatments for rare pediatric diseases, today announced that company management will be participating in the 10th Annual SVB Leerink Global Healthcare Conference from February 24th through February 26th. About Eton PharmaceuticalsEton Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing a...

    02/15/2021ETON
    Eton Pharmaceuticals, Inc.'s (NASDAQ:ETON) Profit Outlook

    With the business potentially at an important milestone, we thought we'd take a closer look at Eton Pharmaceuticals...

    02/8/2021ETON
    Eton Pharmaceuticals Offloads Neurology Portfolio To Azurity Pharmaceuticals For $45M

    Eton Pharmaceuticals Inc (NASDAQ: ETON) has sold its neurology portfolio that includes lamotrigine (ET-105), zonisamide (ET-104), and topiramate (ET-101) product candidates, to Azurity Pharmaceuticals. The marketing applications for all three candidates are currently under review with the FDA. Azurity will be responsible for commercialization following regulatory approval, though Eton will support Azurity in the transition and through regulatory approval. "This transaction allows us to focus on ...

    02/8/2021ETON
    Eton Pharmaceuticals Announces Sale of Neurology Portfolio

    Eton to receive up to $45 million plus royalties on product sales DEER PARK, Ill., Feb. 08, 2021 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative treatments for rare pediatric diseases, today announced that it has sold its neurology portfolio to Azurity Pharmaceuticals. The portfolio includes Eton’s lamotrigine (ET-105), zonisamide (ET-104), and topiramate (ET-101) product candidates, which have...

    01/15/2021ETON
    New Strong Sell Stocks for January 15th

    Here are 5 stocks added to the Zacks Rank 5 (Strong Sell) List today.

    01/14/2021ETON
    Eton Pharmaceuticals Announces Acquisition of Canadian Rights for ALKINDI® SPRINKLE

    DEER PARK, Ill., Jan. 14, 2021 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative treatments for rare pediatric diseases, today announced that it has acquired Canadian rights to ALKINDI® SPRINKLE from Diurnal Group plc (LSE AIM: DNL). Eton Pharmaceuticals currently commercializes ALKINDI® SPRINKLE in the United States as a replacement therapy for Adrenocortical Insufficiency (AI) in children under...

    12/17/2020ETON
    Eton Pharmaceuticals Announces Acceptance for Filing of New Drug Application for Topiramate Oral Solution

    Application Assigned a PDUFA Date of August 6, 2021DEER PARK, Ill., Dec. 17, 2020 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative treatments for rare pediatric diseases, today announced the U.S. Food and Drug Administration (FDA) has accepted for filing the company’s new drug application (NDA) for topiramate oral solution. The application has been assigned a Prescription Drug User Fee Act (PDUF...